| Followers | 928 |
| Posts | 158507 |
| Boards Moderated | 2 |
| Alias Born | 08/13/2010 |
Sunday, May 11, 2025 10:58:45 AM
$LLYSo many children are getting cancer, yet, no one wants to consider vaccines as the culprit.
— Died Suddenly (@DiedSuddenly_) May 10, 2025
This needs to change. @RobertKennedyJr @POTUS pic.twitter.com/ZvK4IgS2T5
Bearish
Nothing I say, post, or do should ever be considered financial advice. I may be holding a long, short or no position. I am NOT or NEVER have I been compensated to post on here or anywhere and all my posts are for entertainment purposes only.
Recent LLY News
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/21/2026 08:20:53 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/21/2026 08:18:58 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/21/2026 08:16:39 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/21/2026 08:14:28 PM
- Form SCHEDULE 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend] • Edgar (US Regulatory) • 04/20/2026 07:25:33 PM
- Lilly to acquire Kelonia Therapeutics to advance in vivo CAR-T cell therapies • PR Newswire (US) • 04/20/2026 01:00:00 PM
- Lilly confirms date and conference call for first-quarter 2026 financial results announcement • PR Newswire (US) • 04/16/2026 02:00:00 PM
- ACHIEVE-4, the longest Phase 3 study of Lilly's Foundayo (orforglipron) to date, reaffirmed its cardiovascular and overall safety profile as well as consistent improvements across key measures of cardiometabolic health • PR Newswire (US) • 04/16/2026 10:45:00 AM
- Eli Lilly reports positive Phase 3 results for Jaypirca in blood cancer study • IH Market News • 04/13/2026 02:27:54 PM
- Lilly's Jaypirca (pirtobrutinib) significantly extended progression-free survival when added to a venetoclax time-limited regimen in patients with previously treated CLL/SLL • PR Newswire (US) • 04/13/2026 10:45:00 AM
- Lilly Introduces Foundayo Oral GLP-1 Weight-Loss Pill in the U.S. • IH Market News • 04/09/2026 01:49:47 PM
- Foundayo™ (orforglipron), Lilly's new oral GLP-1 pill for weight loss, now available in the U.S. • PR Newswire (US) • 04/09/2026 10:45:00 AM
- AC Immune revises collaboration with Eli Lilly on tau-targeting Alzheimer’s therapy • IH Market News • 04/07/2026 01:53:30 PM
- FDA approves Lilly's Foundayo™ (orforglipron), the only GLP-1 pill for weight loss that can be taken any time of day without food or water restrictions • PR Newswire (US) • 04/01/2026 03:30:00 PM
- Hopes of Iran War Resolution Spark Broad Rally on Wall Street • IH Market News • 03/31/2026 08:31:16 PM
- Alkermes shares jump 13% after Lilly announces sleep-disorder acquisition • IH Market News • 03/31/2026 02:55:46 PM
- Novo Nordisk introduces discounted Wegovy subscription plan in the U.S. • IH Market News • 03/31/2026 02:46:32 PM
- Centessa shares soar after Lilly announces multibillion-dollar acquisition deal • IH Market News • 03/31/2026 02:42:29 PM
- Lilly to acquire Centessa Pharmaceuticals to advance treatments for sleep-wake disorders • PR Newswire (US) • 03/31/2026 10:45:00 AM
- Eli Lilly strikes $2.75 billion drug discovery partnership with InSilico • IH Market News • 03/30/2026 09:33:40 AM
- Phase 3b data presented at AAD Annual Meeting show Lilly's Taltz (ixekizumab) plus Zepbound (tirzepatide) delivered superior efficacy for adults with psoriatic arthritis and obesity • PR Newswire (US) • 03/28/2026 07:15:00 PM
- Lilly's EBGLYSS (lebrikizumab-lbkz) delivered up to four years of durable disease control for patients with moderate-to-severe atopic dermatitis • PR Newswire (US) • 03/27/2026 01:00:00 PM
- Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material • Edgar (US Regulatory) • 03/20/2026 08:23:04 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 03/20/2026 08:19:30 PM
